Oncology Ltd, United Kingdom, for (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate for the treatment of soft tissue sarcoma.
In February 2013, Nexus Oncology Ltd changed name to Ockham Europe Limited.
The sponsorship was transferred to Merck KGaA, Germany, in March 2015.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
- What is soft-tissue sarcoma?
Soft-tissue sarcoma is a type of cancer that affects the soft, supportive tissues of the body. It can occur in muscles, blood vessels, fat tissue or in other tissues that support, surround and protect organs. Patients with soft-tissue sarcoma do not usually have symptoms in the early stages of the disease. First symptoms appear when the tumour grows large enough to cause swelling and pain.
Soft-tissue sarcoma is a serious and life-threatening disease particularly when the cancer has spread to other parts of the body.
- What is the estimated number of patients affected by the condition?
At the time of designation, soft tissue sarcoma affected approximately 2.4 in 10,000 people in the European Union (EU). This was equivalent to a total of around 122,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. At the time of designation, this represented a population of 509,000,000 (Eurostat 2012).
- What treatments are available?
At the time of designation, the main treatment for early-stage soft-tissue sarcoma was surgery. For large sarcomas, surgery was usually followed by radiotherapy (treatment with radiation) and chemotherapy (medicines to treat cancer) to kill any cancerous cells that were left behind. Several medicines were authorised in the EU for the treatment of soft-tissue sarcoma.
The sponsor has provided sufficient information to show that (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate might be of significant benefit for patients with soft-tissue sarcoma because early studies show that it might improve the treatment of patients when used in combination with doxorubicin (a chemotherapy medicine). This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
- How is this medicine expected to work?
Soft-tissue sarcomas, like most solid tumours, have areas with poor blood supply and therefore low levels of oxygen. The low level of oxygen in these areas is known to make tumour cells more resistant to standard chemotherapy. This medicine is a prodrug which is expected to be ‘activated’ when it enters these low oxygen regions by converting into a substance called bromo-isophosphoramide mustard, which is toxic to cells. This medicine is intended to be given with standard chemotherapy medicines and this is expected to help kill the tumour cells in low oxygen areas as well as other areas of the tumours.
- What is the stage of development of this medicine?
The effects of the medicinal product have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials with the medicinal product in patients with soft-tissue sarcoma were ongoing.
At the time of submission, the medicinal product was not authorised anywhere in the EU for soft-tissue sarcoma or designated as an orphan medicinal product elsewhere for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 11 January 2011 recommending the granting of this designation.
- Opinions on orphan medicinal product designations are based on the following three criteria
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/12/966: Public summary of opinion on orphan designation: (1-Methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate for the treatment of soft tissue sarcoma||(English only)||19/04/2012||25/03/2015|
|Active substance||(1-Methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate|
|Disease/condition||Treatment of soft-tissue sarcoma|
|Date of decision||05/03/2012|
|Orphan decision number||EU/3/12/966|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor’s contact details
Frankfurter Strasse 250
Tel. +49 6151 72 32 80
Fax +49 6151 72 20 00
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.